PL3558376T3 - Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD - Google Patents

Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD

Info

Publication number
PL3558376T3
PL3558376T3 PL17837879T PL17837879T PL3558376T3 PL 3558376 T3 PL3558376 T3 PL 3558376T3 PL 17837879 T PL17837879 T PL 17837879T PL 17837879 T PL17837879 T PL 17837879T PL 3558376 T3 PL3558376 T3 PL 3558376T3
Authority
PL
Poland
Prior art keywords
steroid
treatment
therapeutic combination
pulmonary surfactant
bpd
Prior art date
Application number
PL17837879T
Other languages
English (en)
Inventor
Laura FABBRI
Fabrizio SALOMONE
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3558376T3 publication Critical patent/PL3558376T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
PL17837879T 2016-12-22 2017-12-19 Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD PL3558376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16206232 2016-12-22
PCT/EP2017/083643 WO2018115013A1 (en) 2016-12-22 2017-12-19 A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd
EP17837879.0A EP3558376B1 (en) 2016-12-22 2017-12-19 A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd

Publications (1)

Publication Number Publication Date
PL3558376T3 true PL3558376T3 (pl) 2022-02-14

Family

ID=57614211

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17837879T PL3558376T3 (pl) 2016-12-22 2017-12-19 Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD

Country Status (13)

Country Link
US (3) US10668110B2 (pl)
EP (1) EP3558376B1 (pl)
JP (2) JP7777392B2 (pl)
KR (1) KR102470549B1 (pl)
CN (1) CN110099695B (pl)
AU (1) AU2017384467B2 (pl)
BR (1) BR112019012922A2 (pl)
CA (1) CA3043792A1 (pl)
ES (1) ES2902578T3 (pl)
MX (1) MX391151B (pl)
PL (1) PL3558376T3 (pl)
RU (1) RU2757902C2 (pl)
WO (1) WO2018115013A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7777392B2 (ja) * 2016-12-22 2025-11-28 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物
MA52353A (fr) * 2018-04-23 2021-04-28 Chiesi Farm Spa Combinaison thérapeutique comprenant un tensioactif pulmonaire et un stéroïde pour la prophylaxie de la dbp
EP3936054A1 (en) * 2020-07-08 2022-01-12 Assistance Publique - Hôpitaux de Paris Method of prognosis of bronchopulmonary dysplasia in premature infants
US12440471B2 (en) * 2021-07-30 2025-10-14 Ayuvis Research, Inc. Compositions and methods for the treatment of bronchopulmonary dysplasia (BPD) and BPD-associated pulmonary hypertension
KR20250172196A (ko) * 2024-05-31 2025-12-09 고려대학교 산학협력단 폐 계면활성제 및 항섬유화제를 포함하는 폐섬유증의 예방 또는 치료용 조성물 및 이의 제조방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
US20060040860A1 (en) * 2004-06-17 2006-02-23 Mario Ruediger Intra-tracheal application of vascular endothelial growth factor (VEGF) for the prevention of lung damages caused by hperoxia
WO2006074296A1 (en) * 2005-01-06 2006-07-13 Discovery Laboratories, Inc. Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
US20070225233A1 (en) 2006-03-27 2007-09-27 Tsu-Fuh Yeh Reducing the risk of chronic lung disease in infants
EP2049554A4 (en) 2006-07-20 2011-06-29 Univ Rochester Medical Ct SYNTHETIC LUNG SURFAKTANT AND ITS USE
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
US8048043B2 (en) 2007-06-08 2011-11-01 Chiesi Farmaceutici S. P. A. Method of administration of a pulmonary surfactant
CA2763402A1 (en) * 2009-05-25 2010-12-02 Chiesi Farmaceutici S.P.A. A therapeutic combination comprising a pulmonary surfactant and a steroid
US8399406B2 (en) 2009-06-05 2013-03-19 Chiesi Farmaceutici S.P.A. Reconstituted surfactant composition containing analogs of surfactant protein B (SP-B) and surfactant protein C (SP-C)
BR112012004651B1 (pt) 2009-09-08 2022-02-08 Chiesi Farmaceutici S.P.A. Surfactante pulmonar exógeno, uso de uma combinação terapêutica, medicamento e kit
US9815869B2 (en) 2012-02-09 2017-11-14 University Of Rochester SP-B and SP-C peptides, synthetic lung surfactants, and use thereof
RU2656185C2 (ru) * 2012-11-21 2018-05-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Реконструированные сурфактанты легких
MX375330B (es) 2013-03-13 2025-03-06 Mallinckrodt Hospital Products Ip Ltd Dispositivos y metodos para monitorizar la oxigenacion durante el tratamiento con el suminitro de oxido nitrico.
WO2015195903A1 (en) * 2014-06-20 2015-12-23 Ino Therapeutics Llc Method of identifying and treating premature infants at risk for bpd
EP3285645B1 (en) * 2015-04-22 2020-08-12 Chiesi Farmaceutici S.p.A. System for effective breath-synchronized delivery of medicament to the lungs
JP7777392B2 (ja) * 2016-12-22 2025-11-28 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 進行性のｂｐｄの処置のための肺サーファクタント及びステロイドを含む処置的組み合わせ物

Also Published As

Publication number Publication date
US20200246391A1 (en) 2020-08-06
JP7777392B2 (ja) 2025-11-28
CN110099695B (zh) 2022-01-25
EP3558376B1 (en) 2021-10-20
MX391151B (es) 2025-03-21
CN110099695A (zh) 2019-08-06
RU2019121940A (ru) 2021-01-22
ES2902578T3 (es) 2022-03-29
KR102470549B1 (ko) 2022-11-25
KR20190099422A (ko) 2019-08-27
US20180177832A1 (en) 2018-06-28
MX2019006263A (es) 2019-08-21
JP2020502242A (ja) 2020-01-23
RU2757902C2 (ru) 2021-10-22
RU2019121940A3 (pl) 2021-03-31
AU2017384467B2 (en) 2023-10-19
AU2017384467A1 (en) 2019-05-30
US20220040239A1 (en) 2022-02-10
BR112019012922A2 (pt) 2019-12-10
CA3043792A1 (en) 2018-06-28
US10668110B2 (en) 2020-06-02
JP2023113852A (ja) 2023-08-16
EP3558376A1 (en) 2019-10-30
WO2018115013A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
IL277648A (en) Medical microbiota for the treatment and/or prevention of food allergy
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL266596A (en) Causes, uses and methods of treating synovialitis
IL250960A0 (en) Combined treatment of sinecriviroc for the treatment of leprosy
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
IL275683A (en) Administering pulses of inhaled nitrous oxide for the treatment of pulmonary hypertension
IL290754A (en) Use of pyridofidine to treat anxiety and depression
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
GB201513461D0 (en) Methods and devices for the production of decellularised tissue scaffolds
IL260352B (en) Methods and preparations for the treatment of neurological disease
PL3558376T3 (pl) Kombinacja terapeutyczna zawierająca surfaktant płucny i steroid do leczenia rozwijającej się BPD
ZA201604785B (en) Halogen treatment of heart attack and ischemic injury
PL3352745T3 (pl) Połączenie dofetylidu i meksyletyny w zapobieganiu i leczeniu migotania przedsionków
IL264950A (en) Combined treatments for the treatment of malignant liver cell carcinoma
IL248875A0 (en) Combinations of formoterol and budesonide for the treatment of chronic obstructive pulmonary disease
GB201504387D0 (en) Materials and methods for the treatment of vascular disease
HUE067036T2 (hu) 2-hidroxibenzilamin alkalmazása pulmonális magas vérnyomás kezelésében és megelõzésében
PL3320901T3 (pl) Dimetyloaminomicheliolid do zastosowania w leczeniu włóknienia płuc
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
PL3701956T3 (pl) Środek profilaktyczny i/lub terapeutyczny na demencję
IL251135A (en) A method for the synthesis of hydroxy-triglycerides and their use for disease prevention and treatment
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
IL272422A (en) Methods for treating diseases of the meninges
IL268844A (en) Peptides and methods of treating dystrophy-related diseases by them
PL3490604T3 (pl) Środek leczniczy do leczenia i/lub zapobiegania endometriozie